No overall damage progression despite persistent inflammation in adalimumab-treated psoriatic arthritis patients: results from an investigator-initiated 48-week comparative magnetic resonance imaging, computed tomography and radiography trial

René Panduro Poggenborg; Charlotte Wiell; Pernille Bøyesen; Annelies Boonen; Paul Bird; Susanne Juhl Pedersen; Inge Juul Sørensen; Ole Rintek Madsen; Ole Slot; Jakob M Møller; Maria Hasselquist; Olga Kubassova; Mikkel Østergaard

doi:10.1093/rheumatology/ket426

No overall damage progression despite persistent inflammation in adalimumab-treated psoriatic arthritis patients: results from an investigator-initiated 48-week comparative magnetic resonance imaging, computed tomography and radiography trial

René Panduro Poggenborg, Charlotte Wiell, Pernille Bøyesen, Annelies Boonen, Paul Bird, Susanne Juhl Pedersen, Inge Juul Sørensen, Ole Rintek Madsen, Ole Slot, Jakob M Møller, Maria Hasselquist, Olga Kubassova, Mikkel Østergaard

Afdeling for Rygkirurgi, Led- og Bindevævssygdomme

37 Citationer (Scopus)

Abstract

Objective. In a comparative conventional MRI, dynamic contrast-enhanced (DCE)-MRI, CT and radiography study, the authors aimed to monitor whether inflammation is reduced or even eliminated and damage halted in PsA patients receiving anti-TNF therapy.Methods. A 48-week prospective open-label investigator-initiated trial of 41 biologic-naive patients treated with 40 mg adalimumab every other week. Hand CT, MRI (according to the PsA MRI scoring system method) and radiography (Sharp-van der Heijde method) were obtained at weeks 0, 6 (only MRI), 24 and 48. Clinical response was assessed by the PsA Response Criteria (PsARC).Results. In the 23 PsARC responders at week 48, significant decreases from baseline in MRI synovitis (mean -2.0, P

Originalsprog	Engelsk
Tidsskrift	Rheumatology (Oxford, England)
Vol/bind	53
Udgave nummer	4
Sider (fra-til)	746-756
Antal sider	10
ISSN	1462-0324
DOI	https://doi.org/10.1093/rheumatology/ket426
Status	Udgivet - apr. 2014

Adgang til dokumentet

10.1093/rheumatology/ket426

Fingeraftryk

Dyk ned i forskningsemnerne om 'No overall damage progression despite persistent inflammation in adalimumab-treated psoriatic arthritis patients: results from an investigator-initiated 48-week comparative magnetic resonance imaging, computed tomography and radiography trial'. Sammen danner de et unikt fingeraftryk.

Citationsformater

Poggenborg, R. P., Wiell, C., Bøyesen, P., Boonen, A., Bird, P., Pedersen, S. J., Sørensen, I. J., Madsen, O. R., Slot, O., Møller, J. M., Hasselquist, M., Kubassova, O., & Østergaard, M. (2014). No overall damage progression despite persistent inflammation in adalimumab-treated psoriatic arthritis patients: results from an investigator-initiated 48-week comparative magnetic resonance imaging, computed tomography and radiography trial. Rheumatology (Oxford, England), 53(4), 746-756. https://doi.org/10.1093/rheumatology/ket426

No overall damage progression despite persistent inflammation in adalimumab-treated psoriatic arthritis patients: results from an investigator-initiated 48-week comparative magnetic resonance imaging, computed tomography and radiography trial. / Poggenborg, René Panduro; Wiell, Charlotte; Bøyesen, Pernille et al.
I: Rheumatology (Oxford, England), Bind 53, Nr. 4, 04.2014, s. 746-756.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Poggenborg, RP, Wiell, C, Bøyesen, P, Boonen, A, Bird, P, Pedersen, SJ , Sørensen, IJ , Madsen, OR, Slot, O, Møller, JM, Hasselquist, M, Kubassova, O & Østergaard, M 2014, 'No overall damage progression despite persistent inflammation in adalimumab-treated psoriatic arthritis patients: results from an investigator-initiated 48-week comparative magnetic resonance imaging, computed tomography and radiography trial', Rheumatology (Oxford, England), bind 53, nr. 4, s. 746-756. https://doi.org/10.1093/rheumatology/ket426

Poggenborg RP, Wiell C, Bøyesen P, Boonen A, Bird P, Pedersen SJ et al. No overall damage progression despite persistent inflammation in adalimumab-treated psoriatic arthritis patients: results from an investigator-initiated 48-week comparative magnetic resonance imaging, computed tomography and radiography trial. Rheumatology (Oxford, England). 2014 apr.;53(4):746-756. doi: 10.1093/rheumatology/ket426

Poggenborg, René Panduro ; Wiell, Charlotte ; Bøyesen, Pernille et al. / No overall damage progression despite persistent inflammation in adalimumab-treated psoriatic arthritis patients : results from an investigator-initiated 48-week comparative magnetic resonance imaging, computed tomography and radiography trial. I: Rheumatology (Oxford, England). 2014 ; Bind 53, Nr. 4. s. 746-756.

@article{dc67bc9ff62c498d94f8250dbb82b7b5,

title = "No overall damage progression despite persistent inflammation in adalimumab-treated psoriatic arthritis patients: results from an investigator-initiated 48-week comparative magnetic resonance imaging, computed tomography and radiography trial",

abstract = "Objective. In a comparative conventional MRI, dynamic contrast-enhanced (DCE)-MRI, CT and radiography study, the authors aimed to monitor whether inflammation is reduced or even eliminated and damage halted in PsA patients receiving anti-TNF therapy.Methods. A 48-week prospective open-label investigator-initiated trial of 41 biologic-naive patients treated with 40 mg adalimumab every other week. Hand CT, MRI (according to the PsA MRI scoring system method) and radiography (Sharp-van der Heijde method) were obtained at weeks 0, 6 (only MRI), 24 and 48. Clinical response was assessed by the PsA Response Criteria (PsARC).Results. In the 23 PsARC responders at week 48, significant decreases from baseline in MRI synovitis (mean -2.0, P ",

author = "Poggenborg, {Ren{\'e} Panduro} and Charlotte Wiell and Pernille B{\o}yesen and Annelies Boonen and Paul Bird and Pedersen, {Susanne Juhl} and S{\o}rensen, {Inge Juul} and Madsen, {Ole Rintek} and Ole Slot and M{\o}ller, {Jakob M} and Maria Hasselquist and Olga Kubassova and Mikkel {\O}stergaard",

year = "2014",

month = apr,

doi = "10.1093/rheumatology/ket426",

language = "English",

volume = "53",

pages = "746--756",

journal = "Rheumatology (Oxford, England)",

issn = "1462-0324",

publisher = "Oxford University Press",

number = "4",

}

TY - JOUR

T1 - No overall damage progression despite persistent inflammation in adalimumab-treated psoriatic arthritis patients

T2 - results from an investigator-initiated 48-week comparative magnetic resonance imaging, computed tomography and radiography trial

AU - Poggenborg, René Panduro

AU - Wiell, Charlotte

AU - Bøyesen, Pernille

AU - Boonen, Annelies

AU - Bird, Paul

AU - Pedersen, Susanne Juhl

AU - Sørensen, Inge Juul

AU - Madsen, Ole Rintek

AU - Slot, Ole

AU - Møller, Jakob M

AU - Hasselquist, Maria

AU - Kubassova, Olga

AU - Østergaard, Mikkel

PY - 2014/4

Y1 - 2014/4

N2 - Objective. In a comparative conventional MRI, dynamic contrast-enhanced (DCE)-MRI, CT and radiography study, the authors aimed to monitor whether inflammation is reduced or even eliminated and damage halted in PsA patients receiving anti-TNF therapy.Methods. A 48-week prospective open-label investigator-initiated trial of 41 biologic-naive patients treated with 40 mg adalimumab every other week. Hand CT, MRI (according to the PsA MRI scoring system method) and radiography (Sharp-van der Heijde method) were obtained at weeks 0, 6 (only MRI), 24 and 48. Clinical response was assessed by the PsA Response Criteria (PsARC).Results. In the 23 PsARC responders at week 48, significant decreases from baseline in MRI synovitis (mean -2.0, P

AB - Objective. In a comparative conventional MRI, dynamic contrast-enhanced (DCE)-MRI, CT and radiography study, the authors aimed to monitor whether inflammation is reduced or even eliminated and damage halted in PsA patients receiving anti-TNF therapy.Methods. A 48-week prospective open-label investigator-initiated trial of 41 biologic-naive patients treated with 40 mg adalimumab every other week. Hand CT, MRI (according to the PsA MRI scoring system method) and radiography (Sharp-van der Heijde method) were obtained at weeks 0, 6 (only MRI), 24 and 48. Clinical response was assessed by the PsA Response Criteria (PsARC).Results. In the 23 PsARC responders at week 48, significant decreases from baseline in MRI synovitis (mean -2.0, P

U2 - 10.1093/rheumatology/ket426

DO - 10.1093/rheumatology/ket426

M3 - Journal article

C2 - 24369412

SN - 1462-0324

VL - 53

SP - 746

EP - 756

JO - Rheumatology (Oxford, England)

JF - Rheumatology (Oxford, England)

IS - 4

ER -